Ningbo Menovo Pharm Co Ltd (SHG:603538) — Market Cap & Net Worth
Market Cap & Net Worth: Ningbo Menovo Pharm Co Ltd (603538)
Ningbo Menovo Pharm Co Ltd (SHG:603538) has a market capitalization of $2.01 Billion (CN¥13.77 Billion) as of May 2, 2026. Listed on the SHG stock exchange, this China-based company holds position #6227 globally and #1366 in its home market, demonstrating a 23.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ningbo Menovo Pharm Co Ltd's stock price CN¥62.46 by its total outstanding shares 220450164 (220.45 Million). Analyse Ningbo Menovo Pharm Co Ltd (603538) cash flow conversion to see how efficiently the company converts income to cash.
Ningbo Menovo Pharm Co Ltd Market Cap History: 2017 to 2026
Ningbo Menovo Pharm Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $488.34 Million to $2.01 Billion (1.50% CAGR).
Ningbo Menovo Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ningbo Menovo Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.30x
Ningbo Menovo Pharm Co Ltd's market cap is 0.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.14x
Ningbo Menovo Pharm Co Ltd's market cap is 6.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $488.34 Million | $605.32 Million | $44.68 Million | 0.81x | 10.93x |
| 2018 | $442.70 Million | $848.96 Million | $96.35 Million | 0.52x | 4.59x |
| 2019 | $560.66 Million | $1.18 Billion | $150.90 Million | 0.48x | 3.72x |
| 2020 | $844.98 Million | $1.19 Billion | $155.96 Million | 0.71x | 5.42x |
| 2021 | $808.11 Million | $1.26 Billion | $142.53 Million | 0.64x | 5.67x |
| 2022 | $823.97 Million | $1.46 Billion | $338.86 Million | 0.57x | 2.43x |
| 2023 | $616.79 Million | $1.22 Billion | $11.59 Million | 0.51x | 53.24x |
| 2024 | $410.01 Million | $1.37 Billion | $66.81 Million | 0.30x | 6.14x |
Competitor Companies of 603538 by Market Capitalization
Companies near Ningbo Menovo Pharm Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Ningbo Menovo Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Ningbo Menovo Pharm Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Ningbo Menovo Pharm Co Ltd's market cap moved from $488.34 Million to $ 2.01 Billion, with a yearly change of 1.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.01 Billion | +224.64% |
| 2025 | CN¥620.66 Million | +51.38% |
| 2024 | CN¥410.01 Million | -33.53% |
| 2023 | CN¥616.79 Million | -25.14% |
| 2022 | CN¥823.97 Million | +1.96% |
| 2021 | CN¥808.11 Million | -4.36% |
| 2020 | CN¥844.98 Million | +50.71% |
| 2019 | CN¥560.66 Million | +26.65% |
| 2018 | CN¥442.70 Million | -9.35% |
| 2017 | CN¥488.34 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Ningbo Menovo Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.01 Billion USD |
| MoneyControl | $2.01 Billion USD |
| MarketWatch | $2.01 Billion USD |
| marketcap.company | $2.01 Billion USD |
| Reuters | $2.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more